
Following a hefty Series B, Silverback Therapeutics quickly pulls in $85M for 'an important growth phase'
Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.
The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.
In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.